menu search

Applied Therapeutics Reports Second Quarter 2023 Financial Results

Applied Therapeutics Reports Second Quarter 2023 Financial Results
Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the FDA as well as EMA Marketing Authorization Application planned in Fall 2023 Phase 3 INSPIRE Trial of govorestat in Sorbitol Dehydrogenase (SORD) Deficiency and ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy on track for data […] The post Applied Therapeutics Reports Second Quarter 2023 Financial Results appeared first on ForexTV... Read More
Posted: Aug 10 2023, 11:00
Author Name: forextv
Views: 022270

Search within

Pages Search Results: